Cerus Co. (NASDAQ:CERS) Director Sells $35,600.00 in Stock

Cerus Co. (NASDAQ:CERS) Director Eric Bjerkholt sold 20,000 shares of the company’s stock in a transaction that occurred on Thursday, December 12th. The stock was sold at an average price of $1.78, for a total transaction of $35,600.00. Following the sale, the director now directly owns 162,133 shares in the company, valued at $288,596.74. This trade represents a 10.98 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Cerus Trading Down 6.5 %

Shares of CERS opened at $1.58 on Thursday. Cerus Co. has a 1-year low of $1.38 and a 1-year high of $2.59. The company has a market capitalization of $293.43 million, a P/E ratio of -14.36 and a beta of 1.24. The company has a debt-to-equity ratio of 1.19, a current ratio of 2.59 and a quick ratio of 1.92. The firm’s 50 day simple moving average is $1.74 and its 200 day simple moving average is $1.91.

Wall Street Analyst Weigh In

Separately, Stifel Nicolaus decreased their price target on shares of Cerus from $6.00 to $3.00 and set a “buy” rating on the stock in a report on Thursday, October 17th.

Institutional Trading of Cerus

Institutional investors and hedge funds have recently made changes to their positions in the stock. Assenagon Asset Management S.A. increased its stake in Cerus by 6.0% in the third quarter. Assenagon Asset Management S.A. now owns 1,257,571 shares of the biotechnology company’s stock valued at $2,188,000 after acquiring an additional 71,007 shares during the last quarter. Hood River Capital Management LLC boosted its holdings in shares of Cerus by 390.4% in the 2nd quarter. Hood River Capital Management LLC now owns 1,469,754 shares of the biotechnology company’s stock worth $2,587,000 after purchasing an additional 1,170,060 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. bought a new position in shares of Cerus during the 3rd quarter valued at about $353,000. The Manufacturers Life Insurance Company raised its holdings in shares of Cerus by 10.9% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 73,372 shares of the biotechnology company’s stock valued at $129,000 after buying an additional 7,209 shares in the last quarter. Finally, Creative Planning lifted its position in Cerus by 51.3% in the 3rd quarter. Creative Planning now owns 24,809 shares of the biotechnology company’s stock worth $43,000 after buying an additional 8,411 shares during the last quarter. Hedge funds and other institutional investors own 78.37% of the company’s stock.

About Cerus

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.